Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b/2, Open-label, Dose Escalation Study of Entinostat in Combination With Pembrolizumab in Patients With Non-small Cell Lung Cancer, With Expansion Cohorts in Patients With Non-small Cell Lung Cancer, Melanoma, and Mismatch Repair-Proficient Colorectal Cancer

Next Previous
Trial Profile

A Phase 1b/2, Open-label, Dose Escalation Study of Entinostat in Combination With Pembrolizumab in Patients With Non-small Cell Lung Cancer, With Expansion Cohorts in Patients With Non-small Cell Lung Cancer, Melanoma, and Mismatch Repair-Proficient Colorectal Cancer

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 24 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Entinostat (Primary) ; Pembrolizumab (Primary)
  • Indications Adenocarcinoma; Colorectal cancer; Malignant melanoma; Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms ENCORE 601; KEYNOTE 142
  • Sponsors Syndax Pharmaceuticals

Most Recent Events

  • 06 Sep 2023 Status changed from active, no longer recruiting to completed.
  • 22 Jun 2023 Planned End Date changed from 1 May 2023 to 1 Jul 2023.
  • 10 Mar 2023 Planned End Date changed from 30 Sep 2022 to 1 May 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top